Heron seeks FDA nod for expanded use of pain relief drug; shares jump

Heron Therapeutics

29/12/2022 15:58

** Shares of drug developer Heron Therapeutics Inc  HRTX.O 
up 11.1% at $2.5 
    ** Co files application with the U.S. Food and Drug
Administration (FDA) for expanding the use of its pain relief
drug in soft tissue and orthopedic surgical procedures 
    ** The drug, Zynrelef, is a non-opioid drug currently
approved to treat pain after foot and ankle, some open
abdominal, and joint replacement surgeries- HRTX 
    ** Co also says drug might qualify for separate
reimbursement payments for additional 3 years under a recent
govt. spending bill, which can help speed up Zynrelef's uptake 
    ** Including session moves, HRTX shares are down ~74.2% YTD 
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))